Rapid Therapeutic Science Laboratories, Inc. RTSL
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -80.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -80.00% | -- |
| Cost of Revenue | -- | -- | -- | 100.00% | -- |
| Gross Profit | -- | -- | -- | -97.67% | -- |
| SG&A Expenses | -71.95% | -75.62% | -40.15% | -19.28% | -- |
| Depreciation & Amortization | -180.43% | -182.22% | -153.62% | -23.81% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -77.22% | -76.60% | -41.95% | -19.27% | -- |
| Operating Income | 77.21% | 76.60% | 41.93% | 19.25% | -- |
| Income Before Tax | 101.74% | 99.39% | 37.42% | -22.43% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 101.74% | 99.39% | 37.42% | -22.43% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 101.74% | 99.39% | 37.42% | -22.43% | -- |
| EBIT | 77.21% | 76.60% | 41.93% | 19.25% | -- |
| EBITDA | 78.14% | 77.37% | 42.12% | 18.22% | -- |
| EPS Basic | 101.50% | 99.25% | 38.14% | -15.10% | -- |
| Normalized Basic EPS | 101.49% | 99.24% | 38.10% | -15.11% | -- |
| EPS Diluted | 101.50% | 99.25% | 38.14% | -15.10% | -- |
| Normalized Diluted EPS | 101.49% | 99.24% | 38.10% | -15.11% | -- |
| Average Basic Shares Outstanding | 2.62% | 0.81% | 1.53% | 4.96% | -- |
| Average Diluted Shares Outstanding | 2.62% | 0.81% | 1.53% | 4.96% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |